Table 3.
Oral drug treatment
| All patients(n = 147) | Appropriate therapy(−)(n = 68) | Appropriate therapy(+)(n = 79) | P value | |
|---|---|---|---|---|
| Amiodarone, n (%) | 90 (61.2) | 48 (70.6) | 42 (53.1) | .031 |
| Sotalol, n (%) | 14 (9.5) | 3 (4.4) | 11 (13.9) | .050 |
| Bepridil, n (%) | 3 (2.0) | 0 (0.0) | 3 (3.8) | .105 |
| Class I AAD, n (%) | 43 (29.3) | 13 (19.1) | 30 (38.0) | .012 |
| Ia | 7 (4.8) | 4 (5.9) | 3 (3.8) | .704 |
| Ib | 36 (24.5) | 9 (13.2) | 27 (34.2) | .004 |
| Ic | 3 (2.0) | 0 | 3 (3.8) | .249 |
| β‐blocker, n (%) | 100 (68.0) | 48 (70.6) | 52 (68.5) | .537 |
| Verapamil, n (%) | 11 (7.5) | 2 (2.9) | 9 (11.4) | .052 |
| Diltiazem, n (%) | 4 (2.7) | 2 (2.9) | 2 (2.5) | .879 |
| Digitalis, n (%) | 7 (4.8) | 3 (4.4) | 4 (5.1) | .853 |
| ACE‐I/ARB, n (%) | 71 (48.3) | 27 (39.7) | 44 (55.7) | .053 |
AAD, antiarrhythmic drug; ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker.